



You are entering a medical section of the Pfizer Landing Page. All materials here are presented for purposes of scientific exchange. They are NOT presented for any promotional purpose.

Sunday, April 10, 2022

CTMS01. Biomarker Advances in Clinical Trials

Great Hall BC, Convention Center

3:00PM–5:00PM CDT

Inotuzumab Ozogamicin

CT027

Exploration of association of leukemic molecular profile with efficacy in patients (pts) with relapsed/refractory acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial

Zhao Y

[View Presentation](#)

Monday, April 11, 2022

CTMS02. Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials

Great Hall BC, Convention Center

2:30PM–4:30PM CDT

Talazoparib

CT031

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity

De Bono J

[View Presentation](#)

Tuesday, April 12, 2022

PO.CL11.03. Cell-Free DNA 2

Exhibit Halls D-H, Poster Section 31

1:30PM–5:00PM CDT

Encorafenib/Binimetinib

3402 / 8

Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Aanalysis of the COLUMBUS study

Dummer R

[View Presentation](#)

PO.CT03.01. Phase III Clinical Trials

Exhibit Halls D-H, Poster Section 35

1:30PM–5:00PM CDT

Lorlatinib

CT223 / 2

Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Bauer T

[View Presentation](#)